NYSE:NVO

Novo Nordisk A/S - NVO Stock Forecast, Price & News

$100.09

-0.30 (-0.30%)

(As of 09/30/2022 03:10 PM ET)

Add

Compare

Today's Range: $99.84
▼
$100.72
50-Day Range: $95.28
▼
$116.93
52-Week Range: $91.51
▼
$122.16

Volume: 39,387 shs
Average Volume: 1.35 million shs
Market Capitalization: $226.50 billion

P/E Ratio: 29.88
Dividend Yield: 0.82%
Price Target: $682.43

Novo Nordisk A/S MarketRank™ Forecast

Analyst Rating: Hold
2.47 Rating Score
Upside/Downside: 581.5% Upside
$682.43 Price Target
Short Interest: Healthy
0.18% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.35
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 22.35%
From $3.40 to $4.16 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

55th out of 1,097 stocks

Pharmaceutical Preparations Industry

13th out of 548 stocks

3.3

Analyst's Opinion

Consensus Rating
Novo Nordisk A/S has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 12 buy ratings, 6 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $682.43, Novo Nordisk A/S has a forecasted upside of 581.5% from its current price of $100.14.
Amount of Analyst Coverage
Novo Nordisk A/S has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.18% of the float of Novo Nordisk A/S has been sold short.
Short Interest Ratio / Days to Cover
Novo Nordisk A/S has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Novo Nordisk A/S has recently decreased by 9.04%, indicating that investor sentiment is improving significantly.

1.7

Dividend Strength

Dividend Yield
Novo Nordisk A/S has a dividend yield of 0.82%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Novo Nordisk A/S does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Novo Nordisk A/S is 24.18%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 19.47% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NVO.

2.4

News and Social Media Coverage

News Sentiment
Novo Nordisk A/S has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Novo Nordisk A/S this week, compared to 4 articles on an average week.
Search Interest
Only 16 people have searched for NVO on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.
MarketBeat Follows
20 people have added Novo Nordisk A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 122% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Novo Nordisk A/S insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.07% of the stock of Novo Nordisk A/S is held by insiders.
Percentage Held by Institutions
Only 6.62% of the stock of Novo Nordisk A/S is held by institutions.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Novo Nordisk A/S are expected to grow by 22.35% in the coming year, from $3.40 to $4.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Novo Nordisk A/S is 29.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.37.
Price to Earnings Ratio vs. Sector
The P/E ratio of Novo Nordisk A/S is 29.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 90.40.
Price to Earnings Growth Ratio
Novo Nordisk A/S has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Novo Nordisk A/S has a P/B Ratio of 20.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Novo Nordisk A/S (NYSE:NVO) Stock

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Stock News Headlines

September 29, 2022 | finance.yahoo.com

Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead Drug Candidate

September 29, 2022 | msn.com

Ventus Therapeutics cuts $70m deal with Danish drug giant Novo Nordisk

September 29, 2022 | finance.yahoo.com

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

September 29, 2022 | theglobeandmail.com

Montreal’s Ventus Therapeutics strikes US$700-million-plus deal with pharma giant Novo Nordisk

September 26, 2022 | msn.com

Ominous Death Cross Forms On Novo Nordisk's Chart

September 23, 2022 | finance.yahoo.com

Novo Nordisk's Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec

September 22, 2022 | seekingalpha.com

Novo Nordisk once-weekly insulin icodec better than daily Tresiba in late-stage study

September 22, 2022 | finance.yahoo.com

More people with type 2 diabetes achieved blood sugar target with once-weekly insulin icodec compared with once-daily insulin degludec

September 21, 2022 | finance.yahoo.com

Novo Nordisk A/S: Diving Into the Drug Pricing Hit From the Inflation Reduction Act, We’ve Reduced Our FVEs by 2%

September 20, 2022 | markets.businessinsider.com

Octagon Therapeutics Enters Inflammation-Focused Research Alliance with Novo Nordisk

September 16, 2022 | thestreet.com

Novo Nordisk (NVO) Stock Drops, Explores Inventing New Forms of Insulin

September 12, 2022 | finance.yahoo.com

Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence

September 8, 2022 | finance.yahoo.com

Novo Nordisk to extend Johnston County growth streak with hundreds of jobs

September 7, 2022 | bizjournals.com

Novo Nordisk makes long-term commitment for Johnston County expansion

September 2, 2022 | finance.yahoo.com

Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition

September 1, 2022 | seekingalpha.com

NVO Novo Nordisk A/S

September 1, 2022 | finance.yahoo.com

Novo Nordisk to Buy Forma Therapeutics in $1.1 Billion Deal

September 1, 2022 | msn.com

Danish drug maker Novo Nordisk buys Watertown biotech Forma for $1.1b

September 1, 2022 | seekingalpha.com

Forma Therapeutics jumps 48% on $1.1B buyout deal with Novo Nordisk

September 1, 2022 | finance.yahoo.com

After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal

September 1, 2022 | finance.yahoo.com

Why Forma Therapeutics Holdings Stock Is On Fire Today

September 1, 2022 | finance.yahoo.com

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

September 1, 2022 | bizjournals.com

Watertown biotech acquired by Novo Nordisk for $1.1B

September 1, 2022 | nasdaq.com

Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal

August 31, 2022 | marketwatch.com

Novo Nordisk Settles DOJ Claims for $6.3M

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.

NVO Company Calendar

Last Earnings: 8/03/2022
Ex-Dividend for 8/23 Dividend: 8/12/2022
Dividend Payable: 8/23/2022
Today: 9/30/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NVO
CUSIP: N/A
CIK: 353278
Web: www.novonordisk.com
Phone: (454) 444-8888
Fax: 45-4449-0555
Employees: 45,000
Year Founded: 1923

Price Target and Rating

Average Stock Price Forecast: $682.43
High Stock Price Forecast: $900.00
Low Stock Price Forecast: $130.00
Forecasted Upside/Downside: +581.8%
Consensus Rating: Hold
Rating Score (0-4): 2.47
Research Coverage: 20 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.35
Trailing P/E Ratio: 29.88
Forward P/E Ratio: 29.44
P/E Growth: 1.77
Net Income: $7.60 billion
Net Margins: 32.14%
Pretax Margin: 39.94%
Return on Equity: 72.10%
Return on Assets: 25.58%

Debt

Debt-to-Equity Ratio: 0.32
Current Ratio: 0.94
Quick Ratio: 0.74

Sales & Book Value

Annual Sales: $22.40 billion
Price / Sales: 10.11
Cash Flow: $3.66 per share
Price / Cash Flow: 27.35
Book Value: $4.78 per share
Price / Book: 20.94

Miscellaneous

Outstanding Shares: 2,262,970,000
Free Float: 2,261,385,000
Market Cap: $226.50 billion
Optionable: Optionable
Beta: 0.47

Social Links

Key Executives

Mr. Lars Fruergaard Jorgensen (Age 56)
Pres, CEO & Member of Management Board
Comp: $4.79M

Mr. Karsten Munk Knudsen (Age 51)
Exec. VP, CFO & Member of the Management Board
Comp: $1.77M

Mr. Henrik Ehlers Wulff (Age 52)
Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board
Comp: $1.86M

Ms. Camilla Sylvest (Age 50)
Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board
Comp: $1.77M

Ms. Monique Carter (Age 49)
Exec. VP, Head of People & Organisation and Member of Management Board
Comp: $1.34M

Mr. Maziar Mike Doustdar (Age 52)
Exec. VP, Head of International Operations & Member of the Management Board

Mr. Douglas J. Langa (Age 56)
Exec. VP, Head of North America Operations & Member of Management Board

Mr. Ludovic Helfgott (Age 48)
Exec. VP, Head of Rare Disease & Member of Management Board

Dr. Martin Holst Lange (Age 52)
Exec. VP, Head of Devel. & Member of the Management Board

Dr. Marcus Schindler Ph.D. (Age 56)
EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NVO Stock - Frequently Asked Questions

Should I buy or sell Novo Nordisk A/S stock right now?: 20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 6 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NVO shares.
View NVO analyst ratings or view top-rated stocks.
What is Novo Nordisk A/S's stock price forecast for 2022?: 20 equities research analysts have issued twelve-month target prices for Novo Nordisk A/S's shares. Their NVO share price forecasts range from $130.00 to $900.00. On average, they anticipate the company's share price to reach $682.43 in the next twelve months. This suggests a possible upside of 579.8% from the stock's current price.
View analysts price targets for NVO or view top-rated stocks among Wall Street analysts.
How have NVO shares performed in 2022?: Novo Nordisk A/S's stock was trading at $112.00 on January 1st, 2022. Since then, NVO shares have decreased by 10.4% and is now trading at $100.39.
View the best growth stocks for 2022 here.
Are investors shorting Novo Nordisk A/S?: Novo Nordisk A/S saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 3,430,000 shares, an increase of 48.5% from the August 15th total of 2,310,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.2% of the company's stock are short sold.
View Novo Nordisk A/S's Short Interest.
When is Novo Nordisk A/S's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our NVO earnings forecast.
How were Novo Nordisk A/S's earnings last quarter?: Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Wednesday, August, 3rd. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.87 by $0.03. The business had revenue of $5.91 billion for the quarter, compared to analysts' expectations of $5.86 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.10% and a net margin of 32.14%.
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?: Novo Nordisk A/S declared a semi-annual dividend on Friday, August 5th. Shareholders of record on Monday, August 15th will be paid a dividend of $0.5836 per share on Tuesday, August 23rd. This represents a yield of 1.1%. The ex-dividend date of this dividend is Friday, August 12th.
Read our dividend analysis for NVO.
Is Novo Nordisk A/S a good dividend stock?: Novo Nordisk A/S (NYSE:NVO) pays an annual dividend of $0.81 per share and currently has a dividend yield of 0.82%. The dividend payout ratio is 24.18%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVO will have a dividend payout ratio of 19.47% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVO.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?: Novo Nordisk A/S updated its FY 2022 earnings guidance on Friday, August, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $22.59 billion-$23.40 billion, compared to the consensus revenue estimate of $23.52 billion.
What is Lars Fruergaard Jørgensen's approval rating as Novo Nordisk A/S's CEO?: 372 employees have rated Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among the company's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Novo Nordisk A/S own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).
What is Novo Nordisk A/S's stock symbol?: Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How do I buy shares of Novo Nordisk A/S?: Shares of NVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Novo Nordisk A/S's stock price today?: One share of NVO stock can currently be purchased for approximately $100.39.
How much money does Novo Nordisk A/S make?: Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $227.18 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.35 on an earnings per share basis.
How many employees does Novo Nordisk A/S have?: The company employs 45,000 workers across the globe.
Does Novo Nordisk A/S have any subsidiaries?: The following companies are subsidiares of Novo Nordisk A/S: Aldaph SpA, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co. Ltd., CS Solar Fund XIV LLC, Calibrium, Corvidia, Corvidia Therapeutics Inc., Dicerna Pharmaceuticals, Dicerna Pharmaceuticals Inc., Emisphere Technologies, Emisphere Technologies Inc., MB2 LLC, NNE A/S, Neotope Neuroscience Limited, Novo Nordisk, Novo Nordisk (China) Pharmaceuticals Co. Ltd., Novo Nordisk (Pty) Limited, Novo Nordisk (Shanghai) Pharma Trading Co. Ltd., Novo Nordisk B.V., Novo Nordisk Canada Inc., Novo Nordisk Colombia SAS, Novo Nordisk Comércio Produtos Farmacêuticos Lda., Novo Nordisk Denmark A/S, Novo Nordisk Egypt LLC, Novo Nordisk Farma OY, Novo Nordisk Farma S.R.L., Novo Nordisk Farma dooel, Novo Nordisk Farmacéutica Limitada, Novo Nordisk Farmacêutica do Brasil Ltda., Novo Nordisk Finance (Netherlands) B.V., Novo Nordisk Health Care AG, Novo Nordisk Hellas Epe., Novo Nordisk Holding Limited, Novo Nordisk Hong Kong Limited, Novo Nordisk Hrvatska d.o.o., Novo Nordisk Hungária Kft., Novo Nordisk Inc., Novo Nordisk India Holding Pte Ltd., Novo Nordisk India Private Limited, Novo Nordisk Kazakhstan LLP, Novo Nordisk Kenya Ltd., Novo Nordisk Lanka (PVT) Ltd, Novo Nordisk Limited, Novo Nordisk Limited Liability Company, Novo Nordisk Ltd, Novo Nordisk Mexico S.A. de C.V., Novo Nordisk North America Operations A/S, Novo Nordisk Norway AS, Novo Nordisk Panama S.A., Novo Nordisk Pars, Novo Nordisk Peru S.A.C., Novo Nordisk Pharma (Malaysia) Sdn Bhd, Novo Nordisk Pharma (Private) Limited, Novo Nordisk Pharma (Singapore) Pte Ltd., Novo Nordisk Pharma (Taiwan) Ltd., Novo Nordisk Pharma (Thailand) Ltd., Novo Nordisk Pharma AG, Novo Nordisk Pharma Argentina S.A., Novo Nordisk Pharma EAD, Novo Nordisk Pharma GmbH, Novo Nordisk Pharma Gulf FZE, Novo Nordisk Pharma Inc., Novo Nordisk Pharma Korea Ltd., Novo Nordisk Pharma Limited, Novo Nordisk Pharma Ltd., Novo Nordisk Pharma Operations (Business Area) Sdn Bhd, Novo Nordisk Pharma Operations A/S, Novo Nordisk Pharma S.A., Novo Nordisk Pharma SARL, Novo Nordisk Pharma SAS, Novo Nordisk Pharma Sp.z.o.o., Novo Nordisk Pharma d.o.o., Novo Nordisk Pharma d.o.o. Belgrade (Serbia), Novo Nordisk Pharmaceutical Industries LP, Novo Nordisk Pharmaceutical Services Sp. z o.o., Novo Nordisk Pharmaceuticals (Philippines) Inc., Novo Nordisk Pharmaceuticals A/S, Novo Nordisk Pharmaceuticals Ltd., Novo Nordisk Pharmaceuticals Pty. Ltd., Novo Nordisk Pharmatech A/S, Novo Nordisk Pharmatech US Inc., Novo Nordisk Production SAS, Novo Nordisk Production Support LLC, Novo Nordisk Produção Farmacêutica do Brasil Ltda., Novo Nordisk Region AAMEO and LATAM A/S, Novo Nordisk Region China A/S, Novo Nordisk Region Europe A/S, Novo Nordisk Region Japan & Korea A/S, Novo Nordisk Research Center Indianapolis Inc., Novo Nordisk Research Center Seattle Inc., Novo Nordisk S.P.A., Novo Nordisk Saglik Ürünleri Tic. Ltd. Sti., Novo Nordisk Saudi for Trading, Novo Nordisk Scandinavia AB, Novo Nordisk Service Centre (India) Pvt. Ltd., Novo Nordisk Slovakia s.r.o., Novo Nordisk Tunisie SARL, Novo Nordisk US Bio Production Inc., Novo Nordisk US Commercial Holdings Inc., Novo Nordisk US Holdings Inc., Novo Nordisk Ukraine LLC, Novo Nordisk Venezuela Casa de Representación C.A., Novo Nordisk d.o.o., Novo Nordisk s.r.o., PT. Novo Nordisk Indonesia, S.A. Novo Nordisk Pharma N.V., UAB Novo Nordisk Pharma, Xellia Pharmaceuticals, Ziylo, and Ziylo Limited.
Read More
How can I contact Novo Nordisk A/S?: Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for the company is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.

This page (NYSE:NVO) was last updated on 9/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Novo Nordisk A/S - NVO Stock Forecast, Price & News

Novo Nordisk A/S MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Novo Nordisk A/S (NYSE:NVO) Stock

NVO Stock News Headlines

NVO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

NVO Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™